The “Basic Drug List†has entered the adjustment period, and it was recently reported that relatively expensive anti-cancer drugs will be included in the revised “Basic Drug Listâ€. Affected by this news, the stocks related to the anti-cancer concept have basically risen last week. However, some experts doubt the operability and sustainability of this system, and people in the industry believe that there are still many variables in the list of anti-cancer drugs in the “essential medicinesâ€.
Anti-cancer drugs into the directory of test ability to pay
An insider of the Ministry of Health told reporters that, given the current strong voice of the masses, amendments to the “Basic Drug List†will consider anti-cancer drugs as well as drugs for treating diabetes and cardiovascular diseases. As for the release date of the revised "Basic Drug List," the person is not clear enough to say "may be released before the middle of next year."
For the anti-cancer drugs into the "basic drug directory", the industry is very different. When interviewed by a reporter from the Southern Capital, Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors, anticipates that the current high-priced anti-cancer drugs will lower prices after entering the base drug, which can significantly ease the pressure on the people and help the patients in the economy more clearly.
Yu Mingde, president of the China Association of Pharmaceutical Enterprise Management, believes that the essence of the basic drug system is to find a balance between the people’s nearly infinite medical needs and the limited national fiscal ability to pay. Therefore, the basic drug list should be inherited from the neglect of in principle.
Yu Mingde introduced whether anticancer drugs belong to essential drugs or whether they are in a debate. If rashly place such undefined drugs into the list of essential drugs, and the prices are still relatively expensive, the ability to pay for state finances is a comparative advantage. hard situation. If it turns out that the national finances cannot sustainably bear this kind of expensive drugs, it is still the common people who suffer from losses.
In addition, it has also been reported that the medical insurance balance in Beijing from January to September this year was only 810 million, and officials of the Beijing Bureau of Human Resources and Social Security came out and rumors that the actual balance is 20 billion “in the optimal state.†.
A doctor at a major hospital is concerned that the revised version of the "Basic Drug List" released in the future will interfere with their prescribing. In an interview with reporters, he said that the future "essential drug directory" will expand from primary hospitals to large hospitals, and may be accompanied by some measure of coercive measures. When they prescribe drugs, these mandatory measures will make them There are numerous restrictions like antibiotics.
Anti-cancer drugs are listed on the agenda
Anti-cancer drugs have not been a novelty in the “catalogue of drugsâ€. As early as April 1, 2009, the Minister of Health Chen Wei clearly stated that basic drugs are not equivalent to cheap drugs and cheap drugs, but instead Frequently-occurring common diseases, the drugs of choice that are effective, reliable, adequate in quantity, reasonably priced, and that the people can enjoy fairly. In the list of essential medicines, not only drugs that treat fevers and fevers but also diabetes medicines, anti-cancer drugs, etc. may also enter the list of essential medicines.
Since then, all kinds of speculations or rumors about "anti-cancer drugs" in the "essential drug list" have been heard. However, on August 18, 2009, the relevant national authorities issued the “National Essential Drug List (Part of the Basic Medical and Health Institutions Equipped with Use)â€. It was found that there was no trace of anticancer drugs at all, and only some large varieties of generic drugs.
At present, due to environmental and lifestyle issues in China, the prevalence of cancer and death rates continue to increase. According to statistics, the prevalence of cancer in China is increasing at a rate of 3%-5% per year, and the mortality rate has increased by 80% in 30 years (WHO data to be investigated). The cost of anti-cancer drugs is higher than that of common drugs, especially targeted drugs with better efficacy and less side effects, and the price is higher. Taking Gleevec, which is recognized as having a good curative effect for the treatment of leukemia at present, for example, the annual cost is around 300,000 RMB. Even the working class in the city is unbearable. Therefore, the common people’s growing appeal for the country to increase its payment for anti-cancer drugs has now coincided with the adjustment period of the “essential drug listâ€. The relevant person from the Ministry of Health told reporters that the government “will consider thisâ€. .
In addition, some people who had worked in the Food and Drug Administration revealed to reporters that the current anticancer drugs are basically concentrated in the hands of foreign pharmaceutical giants in chemical drugs, especially targeted drugs. In the past, in the province of the base drug bidding, the major foreign companies are hard to find traces of their public relations capacity, perhaps in the anti-cancer drug project regain one city.
Related Sections Hype
Just on the weekend of the week when news broke out, shares of anti-cancer-related stocks, such as Hengrui Pharmaceuticals, Yiwei Pharmaceutical, and Hisun Pharmaceutical, had all increased substantially, and many analysts said they were optimistic.
In this regard, there are pharmaceutical investors said that there are still many variables in the current list of anticancer drugs that can enter the "essential drug list." Although the current voice is high, the final result is still unknown. Moreover, even if anticancer drugs eventually enter the “catalogue,†there will be a lag period for the entire industry. Therefore, at least in the medium to long term, at least domestic anti-cancer related industries may not be able to develop as a result.
Anti-cancer drugs into the directory of test ability to pay
An insider of the Ministry of Health told reporters that, given the current strong voice of the masses, amendments to the “Basic Drug List†will consider anti-cancer drugs as well as drugs for treating diabetes and cardiovascular diseases. As for the release date of the revised "Basic Drug List," the person is not clear enough to say "may be released before the middle of next year."
For the anti-cancer drugs into the "basic drug directory", the industry is very different. When interviewed by a reporter from the Southern Capital, Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors, anticipates that the current high-priced anti-cancer drugs will lower prices after entering the base drug, which can significantly ease the pressure on the people and help the patients in the economy more clearly.
Yu Mingde, president of the China Association of Pharmaceutical Enterprise Management, believes that the essence of the basic drug system is to find a balance between the people’s nearly infinite medical needs and the limited national fiscal ability to pay. Therefore, the basic drug list should be inherited from the neglect of in principle.
Yu Mingde introduced whether anticancer drugs belong to essential drugs or whether they are in a debate. If rashly place such undefined drugs into the list of essential drugs, and the prices are still relatively expensive, the ability to pay for state finances is a comparative advantage. hard situation. If it turns out that the national finances cannot sustainably bear this kind of expensive drugs, it is still the common people who suffer from losses.
In addition, it has also been reported that the medical insurance balance in Beijing from January to September this year was only 810 million, and officials of the Beijing Bureau of Human Resources and Social Security came out and rumors that the actual balance is 20 billion “in the optimal state.†.
A doctor at a major hospital is concerned that the revised version of the "Basic Drug List" released in the future will interfere with their prescribing. In an interview with reporters, he said that the future "essential drug directory" will expand from primary hospitals to large hospitals, and may be accompanied by some measure of coercive measures. When they prescribe drugs, these mandatory measures will make them There are numerous restrictions like antibiotics.
Anti-cancer drugs are listed on the agenda
Anti-cancer drugs have not been a novelty in the “catalogue of drugsâ€. As early as April 1, 2009, the Minister of Health Chen Wei clearly stated that basic drugs are not equivalent to cheap drugs and cheap drugs, but instead Frequently-occurring common diseases, the drugs of choice that are effective, reliable, adequate in quantity, reasonably priced, and that the people can enjoy fairly. In the list of essential medicines, not only drugs that treat fevers and fevers but also diabetes medicines, anti-cancer drugs, etc. may also enter the list of essential medicines.
Since then, all kinds of speculations or rumors about "anti-cancer drugs" in the "essential drug list" have been heard. However, on August 18, 2009, the relevant national authorities issued the “National Essential Drug List (Part of the Basic Medical and Health Institutions Equipped with Use)â€. It was found that there was no trace of anticancer drugs at all, and only some large varieties of generic drugs.
At present, due to environmental and lifestyle issues in China, the prevalence of cancer and death rates continue to increase. According to statistics, the prevalence of cancer in China is increasing at a rate of 3%-5% per year, and the mortality rate has increased by 80% in 30 years (WHO data to be investigated). The cost of anti-cancer drugs is higher than that of common drugs, especially targeted drugs with better efficacy and less side effects, and the price is higher. Taking Gleevec, which is recognized as having a good curative effect for the treatment of leukemia at present, for example, the annual cost is around 300,000 RMB. Even the working class in the city is unbearable. Therefore, the common people’s growing appeal for the country to increase its payment for anti-cancer drugs has now coincided with the adjustment period of the “essential drug listâ€. The relevant person from the Ministry of Health told reporters that the government “will consider thisâ€. .
In addition, some people who had worked in the Food and Drug Administration revealed to reporters that the current anticancer drugs are basically concentrated in the hands of foreign pharmaceutical giants in chemical drugs, especially targeted drugs. In the past, in the province of the base drug bidding, the major foreign companies are hard to find traces of their public relations capacity, perhaps in the anti-cancer drug project regain one city.
Related Sections Hype
Just on the weekend of the week when news broke out, shares of anti-cancer-related stocks, such as Hengrui Pharmaceuticals, Yiwei Pharmaceutical, and Hisun Pharmaceutical, had all increased substantially, and many analysts said they were optimistic.
In this regard, there are pharmaceutical investors said that there are still many variables in the current list of anticancer drugs that can enter the "essential drug list." Although the current voice is high, the final result is still unknown. Moreover, even if anticancer drugs eventually enter the “catalogue,†there will be a lag period for the entire industry. Therefore, at least in the medium to long term, at least domestic anti-cancer related industries may not be able to develop as a result.
Qihe Biotech best quality shiitake and oyster mushroom spawn logs
When food tastes very good, you might think it contains too much sugar and fat to stay healthy. But shiitake mushrooms are different. This large succulent mushroom is a delicate food with good nutritional content and many scientifically proven medicinal values. The delicate flavor of shiitake mushrooms adds flavor to almost any dish. In addition, essential amino acids are present in similar proportions to the "ideal protein" of human nutrition. Shiitake is rich in amino acids leucine and lysine, and lacks many grains. It is also a good source of B vitamins. Over the past two decades, scientists have isolated substances from shiitake mushrooms that may play a role in treating and preventing heart disease and cancer.
Ungrouped,High Quality Ungrouped,Ungrouped Details, CN
Shandong Qihe Bio Technology Co.,Ltd. , https://www.qihebio.com